Clinical Trial Update: Potential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating whether adding recombinant human LH improves ovarian stimulation outcomes in women aged 35-40 with infertility.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Infertility

Drugs mentioned

• recombinant human luteinizing hormone (r-hLH) (recombinant human luteinizing hormone)

Snippet

Sponsor: Nanjing University | Conditions: Infertility | Phase 4 | Status: NOT_YET_RECRUITING